{"title":"在ASCO 2017上公布的LATITUDE和STAMPEDE试验为男性高风险转移性前列腺癌患者提供了令人耳目一新的、改变实践的替代方案,但问题仍然存在","authors":"M. Matrana","doi":"10.4172/2168-9857.1000E120","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":89536,"journal":{"name":"British journal of medical & surgical urology","volume":"15 1","pages":"1-1"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"LATITUDE and STAMPEDE Trials Presented at ASCO 2017 offer Refreshing,Practicing-Changing Alternatives to Upfront Docetaxel for Men with High-RiskMetastatic Prostate Cancer, but Questions Remain\",\"authors\":\"M. Matrana\",\"doi\":\"10.4172/2168-9857.1000E120\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":89536,\"journal\":{\"name\":\"British journal of medical & surgical urology\",\"volume\":\"15 1\",\"pages\":\"1-1\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British journal of medical & surgical urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2168-9857.1000E120\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of medical & surgical urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2168-9857.1000E120","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
LATITUDE and STAMPEDE Trials Presented at ASCO 2017 offer Refreshing,Practicing-Changing Alternatives to Upfront Docetaxel for Men with High-RiskMetastatic Prostate Cancer, but Questions Remain